is the united states the biggest consumer of prescription drugs in the world?
“aren't we the biggest consumer of prescription drugs in the whole world?”
a host said on Huberman Lab, 2026-09-21, at 33:33. hear it in context →
first, the part that holds
measured in money, yes. in 2022 the united states accounted for 62.4 percent of all prescription drug sales across 34 wealthy countries, more than the other 33 combined, and its market is more than three times the size of the next-largest country's, china's.
what we found when we went and looked
a 2024 report written by RAND for the office of the assistant secretary for planning and evaluation (part of HHS) used IQVIA MIDAS data. it found that the united states had $617.2 billion of the $988.9 billion in 2022 prescription drug sales across 34 OECD countries, which is 62.4 percent. it also had 23.8 percent of volume (261.6 billion standard units), slightly more than japan's 20.0 percent (219.8 billion units). china is the main non-OECD market. a 2023 peer-reviewed review, citing IQVIA, puts china at about $185 billion in sales against about $620 billion for the united states. so the united states is the world's largest prescription drug market by spending. the gap in spending comes mostly from price, not from how many pills people take. US prices across all drugs were 278 percent of prices in the comparison countries, while US prices for unbranded generics, which make up 90 percent of US prescriptions, were 67 percent of theirs.
assertion by assertion
| assertion | verdict | what the record says |
|---|---|---|
| the united states is the largest consumer of prescription drugs in the world, measured by money spent | confirmed | 2022 IQVIA MIDAS data in the HHS-commissioned report: US sales of $617.2 billion out of $988.9 billion across 34 OECD countries, which is 62.4 percent and more than the other 33 countries combined ($371.7 billion). a 2023 review in health care science, citing IQVIA, puts china, the second-largest market, at about $185 billion against about $620 billion for the united states. these are manufacturer invoice prices before US rebates. countries outside the OECD other than china are not in the table. [1][3] |
| the united states also takes the largest number of prescription doses | unverifiable | within the 34 OECD countries, yes, narrowly: 261.6 billion standard units (23.8 percent) against japan's 219.8 billion (20.0 percent). the dataset leaves out china, india and brazil, so it cannot say whether the united states is the largest by volume worldwide. it measures 'standard units' (one tablet, one 5 mL dose, one vial), which is not the same as courses of treatment. [1] |
| americans take more prescription drugs per person than anyone else | false | japan's 219.8 billion standard units went to a population well under half the size of the US population. by our own rough arithmetic, that is about twice as many units per person as the united states (261.6 billion). by the same arithmetic, south korea, the united kingdom and turkey also come out above the united states per person. the report does not do this per-person calculation; the population figures are ours, not from the report. [1] |
| US per-person spending on drugs is the highest among wealthy countries | confirmed | a 2018 JAMA study of 11 high-income countries using 2016 data: pharmaceutical spending per person was $1,443 in the united states against a range of $466 to $939 in the other ten countries. |
| the spending lead reflects prices more than use | confirmed | across all drugs, US manufacturer gross prices were 278 percent of prices in the 33 comparison countries in 2022, and brand-name originator prices were 422 percent (308 percent after a rebate adjustment). unbranded generics make up 90 percent of US prescription volume, and their US prices were 67 percent of the comparison countries' prices. [1][2] |
both directions
for the speaker: the spending figures are not close. the united states accounts for 62.4 percent of OECD prescription drug sales and spends more than the next 33 wealthy countries combined. its market is more than three times the size of china's. its per-person drug spending ($1,443 in 2016) was about 1.5 to 3 times that of other high-income countries. even counting doses, the united states recorded more standard units than any other OECD country in 2022. use is also common at home: CDC survey data found 45.8 percent of the US population had used a prescription drug in the past 30 days in 2015-2016.
against: 'consumer' can mean quantity, not money, and by quantity the picture changes. the US share of OECD volume (23.8 percent) is barely above japan's (20.0 percent), even though japan has well under half as many people. per person, japan, south korea, the united kingdom and turkey all record more standard units than the united states. the spending lead comes mainly from prices: brand-name drugs cost about four times as much in the united states. americans use mostly generics (90 percent of US volume), and US generic prices are lower than in the comparison countries.
what this cannot say
the OECD sales and volume table covers 34 countries. it leaves out china, india, brazil and the rest of the non-OECD world, so world volume rankings cannot be settled from it. the china comparison comes from a review article quoting IQVIA figures without a stated year. the US figures are manufacturer invoice prices before confidential rebates, which the report estimates cut US brand prices by about 37 percent. even after that adjustment the united states remains the largest market. 'standard units' count tablets and doses, not people treated or courses of therapy. the per-person comparisons are our own rough arithmetic using approximate population figures that are not in the report. the CDC usage figure is from 2015-2016 and has no international counterpart in these sources. we did not have a primary source giving a worldwide total.
sources, each one fetched and read
- RAND Health Care for HHS ASPE, International Prescription Drug Price Comparisons: Estimates Using 2022 Data, contractor project report, February 2024 What we read there: Table 2.1: total sales of $988.9 billion and total volume of 1,099.1 billion standard units across OECD countries; 'The United States accounted for 62.4 percent of sales but only 23.8 percent of volume.' Japan: 6.6 percent of sales, 20.0 percent of volume (219.8 billion units against 261.6 billion for the US). Footnote 39: the OECD set includes eight of the ten countries with the most drug spending in 2018, the exceptions being China and Brazil. Fetched 2026-10-19 (HTTP 200). https://www.aspe.hhs.gov/sites/default/files/documents/277371265a705c356c968977e87446ae/international-price-comparisons.pdf
- HHS ASPE, Comparing Prescription Drugs in the U.S. and Other Countries: Prices and Availability, January 31, 2024 What we read there: In 2022, U.S. prices across all drugs (brands and generics) were nearly 2.78 times as high as prices in the comparison countries. Fetched 2026-10-19 (HTTP 200). https://www.aspe.hhs.gov/reports/comparing-prescription-drugs
- Chen V, Shao W. Balancing medical innovation and affordability in the new healthcare ecosystem in China: review of pharmaceutical pricing and reimbursement policies. Health Care Science, 2023. doi:10.1002/hcs2.76 What we read there: China surpassed Japan to become the second-largest pharmaceutical market in the world in 2016; 'China supplies 185 billion USD in sales, and the United States has some 620 billion USD' (attributed to IQVIA Market Prognosis). Fetched 2026-10-19 (HTTP 200). https://pmc.ncbi.nlm.nih.gov/articles/PMC11080678/
- CDC National Center for Health Statistics, Prescription Drug Use in the United States, 2015-2016, NCHS Data Brief No. 334, May 2019 What we read there: In 2015-2016, 45.8% of the U.S. population used prescription drugs in the past 30 days (NHANES). Fetched 2026-10-19 (HTTP 200). https://www.cdc.gov/nchs/products/databriefs/db334.htm
speakers are described by role, not named. one sentence is quoted under fair use, with attribution and a link to the original at the timestamp; we do not re-host audio or video. nothing on this page is a reason to start, stop or change a medication. if you have the file behind anything marked unverifiable, the research board is where people can answer. adam